Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
| Autor: | Uros Markovic, Melania Carlisi, Vittorio Del Fabro, Emilia Cotzia, Clotilde Cangialosi, Anxur Merenda, Bruno Garibaldi, Valeria Calafiore, Francesco Acquaviva, Marina Parisi, Alessandra Romano, Renato Scalone, Salvatore Leotta, Santo Neri, Massimo Poidomani, Concetta Conticello, Giuseppe Sapienza, Donato Mannina, Vanessa Innao, Valerio Leotta, Daniele Tibullo, Maurizio Musso, Cinzia Maugeri, Giovanni Cardinale, Enrica Antonia Martino, Giuseppe Longo, Francesco Di Raimondo, Giuseppina Uccello |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Salvage therapy lcsh:Medicine Context (language use) Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine salvage therapy KRd regimen multiple myeloma Multiple myeloma Lenalidomide Cumulative dose business.industry lcsh:R General Medicine medicine.disease Carfilzomib Clinical trial Tolerability chemistry 030220 oncology & carcinogenesis business 030215 immunology medicine.drug |
| Zdroj: | Journal of Clinical Medicine, Vol 8, Iss 6, p 877 (2019) Journal of Clinical Medicine Volume 8 Issue 6 |
| Popis: | Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years patients had received a median of two previous lines of treatment (range 1&ndash 10) and 52% were refractory to previous treatment. Median number of KRd cycles was 12 (2&ndash 29), with a mean duration of treatment of 12 months 21 patients had received at least 18 cycles. Overall response rate was 61%, including 18% complete response. Median PFS was 22.9 months, median OS was not reached. Creatinine clearance > 30 mL/min, quality of the best achieved response and standard Fluorescence In Situ Hybridization (FISH) risk were independent predictors of favorable outcome. Patients who received the full-dosage of carfilzomib in the first two cycles had a better outcome. Conclusions: KRd was effective and well tolerated and in a considerable proportion of patients, therapy continued beyond the 18th cycle. The finding of a better outcome in patients with the higher cumulative dose of carfilzomib in the first two cycle encourages to maintain the maximum tolerated dose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|